132 related articles for article (PubMed ID: 38272173)
1. A potential novel cancer immunotherapy: Agonistic anti-CD40 antibodies.
Jian CZ; Lin L; Hsu CL; Chen YH; Hsu C; Tan CT; Ou DL
Drug Discov Today; 2024 Mar; 29(3):103893. PubMed ID: 38272173
[TBL] [Abstract][Full Text] [Related]
2. Agonistic CD40 antibodies and cancer therapy.
Vonderheide RH; Glennie MJ
Clin Cancer Res; 2013 Mar; 19(5):1035-43. PubMed ID: 23460534
[TBL] [Abstract][Full Text] [Related]
3. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
[TBL] [Abstract][Full Text] [Related]
4. CD40 activation as potential tool in malignant neoplasms.
Ottaiano A; Pisano C; De Chiara A; Ascierto PA; Botti G; Barletta E; Apice G; Gridelli C; Iaffaioli VR
Tumori; 2002; 88(5):361-6. PubMed ID: 12487551
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting.
Salomon R; Rotem H; Katzenelenbogen Y; Weiner A; Cohen Saban N; Feferman T; Amit I; Dahan R
Nat Cancer; 2022 Mar; 3(3):287-302. PubMed ID: 35190724
[TBL] [Abstract][Full Text] [Related]
6. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA
Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184
[TBL] [Abstract][Full Text] [Related]
7. Harnessing the potential of CD40 agonism in cancer therapy.
Zhou Y; Richmond A; Yan C
Cytokine Growth Factor Rev; 2024 Feb; 75():40-56. PubMed ID: 38102001
[TBL] [Abstract][Full Text] [Related]
8. The use of agonistic anti-CD40 therapy in treatments for cancer.
Khong A; Nelson DJ; Nowak AK; Lake RA; Robinson BW
Int Rev Immunol; 2012 Aug; 31(4):246-66. PubMed ID: 22804570
[TBL] [Abstract][Full Text] [Related]
9. The Immune Revolution: A Case for Priming, Not Checkpoint.
Vonderheide RH
Cancer Cell; 2018 Apr; 33(4):563-569. PubMed ID: 29634944
[TBL] [Abstract][Full Text] [Related]
10. Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy.
Enell Smith K; Deronic A; Hägerbrand K; Norlén P; Ellmark P
Expert Opin Biol Ther; 2021 Dec; 21(12):1635-1646. PubMed ID: 34043482
[No Abstract] [Full Text] [Related]
11. Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response.
Osada T; Nagawa H; Takahashi T; Tsuno NH; Kitayama J; Shibata Y
J Immunother; 2002; 25(2):176-84. PubMed ID: 12074047
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of agonistic anti-CD40 on human mature and immature dendritic cells: the Janus face of anti-CD40.
de Goër de Herve MG; Durali D; Tran TA; Maigné G; Simonetta F; Leclerc P; Delfraissy JF; Taoufik Y
Blood; 2005 Oct; 106(8):2806-14. PubMed ID: 15994291
[TBL] [Abstract][Full Text] [Related]
13. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH
J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
[TBL] [Abstract][Full Text] [Related]
15. New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5).
Piechutta M; Berghoff AS
ESMO Open; 2019; 4(Suppl 3):e000510. PubMed ID: 31275618
[TBL] [Abstract][Full Text] [Related]
16. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.
van Hooren L; Georganaki M; Huang H; Mangsbo SM; Dimberg A
Oncotarget; 2016 Jul; 7(31):50277-50289. PubMed ID: 27385210
[TBL] [Abstract][Full Text] [Related]
18. Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.
Dovedi SJ; Lipowska-Bhalla G; Beers SA; Cheadle EJ; Mu L; Glennie MJ; Illidge TM; Honeychurch J
Cancer Immunol Res; 2016 Jul; 4(7):621-630. PubMed ID: 27241845
[TBL] [Abstract][Full Text] [Related]
19. The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation.
Sum E; Rapp M; Dürr H; Mazumdar A; Romero PJ; Trumpfheller C; Umaña P
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292514
[TBL] [Abstract][Full Text] [Related]
20. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
